Comparable survival of African-Americans and Caucasian patients with multiple myeloma: A hospital-based study including 117,926 patients.

person Ehsan Malek Division of Hematology and Oncology, University of Cincinnati, Cincinnati, OH info_outline Ehsan Malek, Kamal Chamoun, Paolo Fabrizio Caimi, Stanton L. Gerson, Ben Kent Tomlinson, Seema Patel, Marcos J.G. De Lima, Pingfu Fu

Authors person Ehsan Malek Division of Hematology and Oncology, University of Cincinnati, Cincinnati, OH info_outline Ehsan Malek, Kamal Chamoun, Paolo Fabrizio Caimi, Stanton L. Gerson, Ben Kent Tomlinson, Seema Patel, Marcos J.G. De Lima, Pingfu Fu Organizations Division of Hematology and Oncology, University of Cincinnati, Cincinnati, OH, Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, Adult Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, Adult Malignant Hematology, Seidman Cancer Center, Cleveland, OH, University Hospitals Seidman Cancer Center and Case Comprehensive Cancer Center, Cleveland, OH, Department of Population and Quantitative Health Science, Case Western Reserve University, Cleveland, OH Abstract Disclosures Research Funding Other Background: Multiple Myeloma (MM) counts the most common hematologic malignance among African-Americans with twice the incidence of whites. The outcomes have greatly improved during the last 15 years, however with changing demographics there is an increasing focus on how various subgroups, based on race and ethnicity may be benefiting from survival improvement in MM. Previous studies showed that if access to care is assured, racial disparity-driven differences in outcome may be mitigated. Here, we conducted a study using the National Cancer Data Base (NCDB), which covers more than 70% of cancer pts in the USA, to evaluate survival patterns by race. Methods: MM patients (pts) diagnosed between years 2005 and 2014 and reported to the NCDB were analyzed (n = 117926). Pts were divided in three groups based on the year (y) of diagnosis (2005-07, 2008-10 and 2011-14). Kaplan-Meier method and log-rank test were used for overall survival analysis (OS). The effect size, hazard ratio (HR), of race on OS was estimated by Cox model adjusted by confounders. Results: Median age at diagnosis was 67 y (19 - 90); 55% were males. Median follow up was 30 months (m) (0 - 145). Median OS for white and black pts was 46 m (95% CI: 45.4 - 46.6) and 50.6 m (95% CI: 49.1 - 52.3), respectively (p < 0.0001). Black had longer OS compared to white pts by univariable analysis in all three study periods, noticeably with a trend toward higher survival benefit in most recent years. After adjusting for a variety of factors there was no statistically significant difference between the two racial groups (Table). Conclusions: This large study confirmed that after adjusting for confounding factors survival is similar for white and black MM pts. Summary of overall survival by race and period of diagnosis. Period Median OS (m) Unadjusted HR (95% CI) P-value Adjusted HR (95% CI) £ p-value White Black 2005-07 35.1 36.5 1.05 (1.01, 1.08) 0.008 0.85 (0.18, 4.09) 0.835 2008-10 46.1 51.2 1.1 (1.06, 1.14) < 0.0001 1.2 (0.83, 1.72) 0.334 2011-14 52.9 60.3 1.11 (1.07, 1.15) < 0.0001 1.04 (0.95, 1.14) 0.414 £ Adjusted for age, gender, tumor (primary vs. secondary), Charlson comorbidity score, regional income and type of hospital (academic vs. others).